Wave Life Sciences (WVE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.34
- Estimate
- -$0.30
- Surprise
- -14.4%
- Revenue (period 2026-06-30)
- $2.3M
- Score today
- 4.3/10
Revenue source: mixed.
How the report landed
Wave Life Sciences (WVE) reported a wider loss than forecast — adjusted EPS of -$0.34 against the -$0.30 estimate (a 14.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates WVE Sell at 4.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -14.4% surprise compares with a +5.6% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $17.68 vs price $3.16 — ratio 5.6×). Rejected, falling back to technical TP.
- Quality below floor (1.8 < 4.0)
- Momentum score 1.8/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.16
- Price target
- $4.36
- Stop
- $2.95
- Upside to target
- +37.9%
Risk check: RSI 29 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
WVE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $628.6M
- P/E (fwd)
- -2.7
- 52-week range
- $3.04–$21.73
- Off 52-week high
- 85.5%
- RSI (14)
- 29
- Volume vs avg
- 0.42×
- Score today
- 4.3/10